Pharmacokinetics of ADS-5102 (amantadine) Extended Release Capsules Administered Once-Daily at Bedtime for the Treatment of Dyskinesia

被引：0
|
作者：
Hauser, Robert [1 ]
Pahwa, Rajesh [2 ]
Wargin, William [3 ]
Souza-Prien, Cindy [4 ]
McClure, Natalie [4 ]
Patni, Rajiv [4 ]
Went, Gregory [4 ]
机构：
[1] Univ South Florida, Tampa, FL USA
[2] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[3] Nuventra Pharma Serv Inc, Raleigh, NC USA
[4] Adamas Pharmaceut Inc, Emeryville, CA USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.043
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
    Robert A. Hauser
    Rajesh Pahwa
    William A. Wargin
    Cindy J. Souza-Prien
    Natalie McClure
    Reed Johnson
    Jack T. Nguyen
    Rajiv Patni
    Gregory T. Went
    Clinical Pharmacokinetics, 2019, 58 : 77 - 88
  • [2] Pharmacokinetics of ADS-5102 (Amantadine) ExtendedRelease Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
    Hauser, Robert A.
    Pahwa, Rajesh
    Wargin, William A.
    Souza-Prien, Cindy J.
    McClure, Natalie
    Johnson, Reed
    Nguyen, Jack T.
    Patni, Rajiv
    Went, Gregory T.
    CLINICAL PHARMACOKINETICS, 2019, 58 (01) : 77 - 88
  • [3] ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia
    Pahwa, Rajesh
    Hauser, Robert A.
    JAMA NEUROLOGY, 2017, 74 (12) : 1507 - 1508
  • [4] ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia Reply
    Shukla, Aparna Wagle
    JAMA NEUROLOGY, 2017, 74 (12) : 1508 - 1508
  • [5] Efficacy and safety of ADS-5102 (amantadine) extended-release capsules for treating levodopa-induced dyskinesia
    Agarwal, Pinky
    Ray, Sudeshna
    Burdick, Daniel
    Griffith, Alida F.
    Madan, Arina
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (10): : 625 - 634
  • [6] The Development of ADS-5102 (Amantadine ER Capsules) for the Treatment of Levodopa-induced Dyskinesia
    McClure, Natalie
    NEUROTHERAPEUTICS, 2015, 12 (03) : 679 - 680
  • [7] Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease
    Elmer, Lawrence W.
    Juncos, Jorge L.
    Singer, Carlos
    Truong, Daniel D.
    Criswell, Susan R.
    Parashos, Sotirios
    Felt, Larissa
    Johnson, Reed
    Patni, Rajiv
    CNS DRUGS, 2018, 32 (04) : 387 - 398
  • [8] Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
    Lawrence W. Elmer
    Jorge L. Juncos
    Carlos Singer
    Daniel D. Truong
    Susan R. Criswell
    Sotirios Parashos
    Larissa Felt
    Reed Johnson
    Rajiv Patni
    CNS Drugs, 2018, 32 : 399 - 400
  • [9] ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 EASE LID study
    Pahwa, R.
    Tanner, C. M.
    Hauser, R. A.
    Nausieda, P.
    Truong, D. D.
    Hull, K.
    Agarwal, P.
    Johnson, R.
    Ruby, A. E.
    McClure, N. L.
    Stempien, M. J.
    MOVEMENT DISORDERS, 2016, 31 : S663 - S663
  • [10] ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study) A Randomized Clinical Trial
    Pahwa, Rajesh
    Tanner, Caroline M.
    Hauser, Robert A.
    Isaacson, Stuart H.
    Nausieda, Paul A.
    Truong, Daniel D.
    Agarwal, Pinky
    Hull, Keith L.
    Lyons, Kelly E.
    Johnson, Reed
    Stempien, Mary Jean
    JAMA NEUROLOGY, 2017, 74 (08) : 941 - 949
12345